Clinical Trials
7 trialsNCT03860272 2026-03-30
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT02936102 2025-11-14
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT04000529 2025-09-30
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
Phase 1 Terminated
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT03365791 2022-05-27
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis
Phase 2 Completed
NCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn